(1/12, Bankhead) reported, "Treatment with an angiotensin receptor blocker (ARB) did not slow progression of end-stage renal disease (ESRD) or its precursor in kidney transplant recipients," according to a study published online in the Journal of the American Society of Nephrology. Researchers found that "the composite endpoint of doubling the fraction of cortical interstitial compartment volume or ESRD from interstitial fibrosis/tubular atrophy (IF/TA) did not differ significantly between patients treated with losartan and those who received placebo." Additionally, "active therapy with the ARB...did not reduce the rate of the composite of ESRD, death, and doubling of serum creatinine."
No comments:
Post a Comment